Jump to content
IndiaDivine.org

Aids Article.

Rate this topic


Guest guest

Recommended Posts

What can jump massive cell junctions in a single bound?Dodge " bullets " faster

than the speed of light?Is it a bird?Is it a plane?Is it Superman?no!!!It's

HIV!!!! http://www.virusmyth.net/aids/data/ehremarks.htm REMARKS ON METHODS

FOR RETROVIRAL ISOLATION

By Etienne de Harven

 

Continuum Spring 1998

 

 

Dr. Etienne de Harven is emeritus Professor of Pathology, University of Toronto.

He worked in electron microscopy (EM) primarily on the ultrastructure of

retroviruses throughout his professional career of 25 years at the Sloan

Kettering Institute in New York and 13 years at the University of Toronto. In

1956 he was the first to report on the EM of the Friend virus in murine (mouse)

leukemia, and in 1960, to coin the word " budding " to describe steps of virus

assembly on cell surfaces. He will deliver a speech at the 12th World AIDS

Conference in Geneva (June 28-July 3) at the session " HIV-testing: Open

Questions about Specificity " .

 

The most impressive developments of molecular genetics over the past 20 years do

not make Robert Koch's postulates obsolete. The first of these postulates

indicates that to be considered as pathogenic, a microorganism should be

isolated in every single case of the disease. Still, according to E. Papadopulos

et all and S. Lanka (2) isolation of HIV from fresh plasma of AIDS patients has

never been achieved under any circumstances. Moreover, and most surprisingly,

the " efficiency " of current antiviral therapeutic protocols (AZT tri-therapy) is

being measured by determining " viral load " in the plasma of treated patients.

" Viral load " implies viremia I.e. the presence of circulating viral particles in

the peripheral blood. The virus incriminated being allegedly a retrovirus, this

would have been the time to remember that the morphology of such viruses in

several animal experimental tumors and leukemias had been extensively

characterised by transmission electron microscopy (EM) over the

past 40 years, the viral particles having a characteristic ultrastructure and a

diameter ranging between 100 and 120 um. Some of them had been studied by

methods of high resolution transmission electron microscopy.(3) In the 1960s,

transmission electron microscopy was by far the best available method to

identify viruses within or around diseased cells. Consequently, many cancer

research centers all around the world, started to compete for the best equipment

and training in EM, aiming at the demonstration in human malignancies of viruses

similar to those which had just been recognized as significantly associated with

tumors and leukemias of several laboratory animals. This approach to cancer

research appeared highly justified when Lwoff, Horne and Tournier proposed to

classify all viruses primarily on the basis of their morphological features

demonstrated by electron microscopy.(4) Identification of viruses by EM in

leukemic animal tissues became unambiguous when steps in virus

assembly, i.e. the 'budding' of complete virions from the surface of the

infected cells, were described.(5) In spite of considerable efforts, the search

for similar, typical viruses in human malignancies remained entirely negative.

Pleomorphic membranous microvesicles, approaching viral size, and frequently

described in the literature on human malignancies as " virus-like particles " were

without any pathogenic significance. As stated in 1965, typical RNA tumor

viruses have never been observed in association with human neoplasia.(6)

 

Concentrations of retroviruses from murine and avian leukemic tissue homogenates

were reproducibly achieved permitting titration of infectivity into receptive

laboratory animals. This was not, however, an easy approach to the problem of

virus purification, large amounts of microvesicles and cell debris being usually

present. As far as virus purification was concerned, it soon became evident that

when viremia is present, blood plasma was far better than tissue homogenates for

efficient virus isolation and purification.

 

In the case of RNA tumor viruses, now called retroviruses, the demonstration of

viremia in the blood plasma of experimental leukemic animals (chickens and mice)

was published more than 35 years ago. A most efficient purification method

including ultrafiltration and ultracentrifugation of a 1/1 dilution of plasma in

heparinized Ringer's solution, allowed me to demonstrate packed retroviruses by

transmission electron microscopy (7) in thin sections of pellets obtained by

high speed centrifugation of the purified virus, quite clearly establishing that

the amount of contaminating cell debris was remarkably small, a conclusion which

could never have been reached by using the negative staining EM method. Using

this simple ultrafiltration procedure, virions were never exposed to hypertonic

shock. However, sedimentation in sucrose density gradients, at the density of

1.16 gm/ml, soon became the most popular method for retrovirus purification.(8)

Interestingly, it was very well known by

electron microscopists in the 1960s, that sharp bands sedimenting at the

density of 1.16 frequently contained large amounts of microvesicles and cell

debris of non-viral nature. These debris just happened to sediment in sucrose

gradients at a density very similar to that of retroviruses clearly indicating

that finding a " sharp band " at the density of 1.16 gm/ml was of little

significance and was certainly far from any demonstration of retroviruses

isolation.

 

But this conclusion was based on EM findings, and around 1970 the faith in

retroviral oncology was assuming quasi-religious proportions! If EM cannot

demonstrate viruses in the 1.16 bands, let us forget about EM and rely on other

" markers " !

 

When around 1980, R. Gallo and his followers attempted to demonstrate that

certain retroviruses can be suspected of representing; human pathogens, to the

best of my bibliographical recollection, electron microscopy was never used to

demonstrate directly viremia in the studied patients. Why? Most probably, EM

results were negative and swiftly ignored! But over-enthusiastic

retrovirologists continued to rely on the identification of so-called " viral

markers " , attempting to salvage their hypothesis.

 

When retrovirus particles are legion, the study of molecular markers can be

useful, and provide an approach to quantification probably better than direct

particle counting under the EM (which I always found very difficult). But when,

using EM, retrovirus particles are absent relying exclusively on 'markers' is a

methodological nonsense. 'Markers' of what?

 

Nevertheless, for the past ten years, HIV research and clinical therapeutic

trials have been primarily based on the study of several HIV " markers " .

 

First the antibody. Elisa, then Western Blot tests were hastily developed (at

sizable financial profit eagerly split between the Pasteur Institute and the

US). " Seropositivity " became synonymous with the disease itself, plunging an

entire generation into behavioral panic, and exposing hundreds of thousands of

people to 'preventive' antiviral AZT therapy which actually hastened the

appearance of severe or lethal immunodeficiency syndrome. Appropriate controls

were apparently never carried out or were never published. Still, back in 1993

it became clear that the so-called HIV antibody tests badly lacked specificity,

(9) cross-reactivity being observed with patients suffering from a long list of

pathological conditions including malaria, leprosy, auto-immune diseases and

many more.

 

Secondly, 'viral proteins'. Several proteins have been identified as 'HIV

markers', most frequently because they were identified in a variety of 1.16

bands. The case of the p24 " viral " antigen is a significant example and its lack

of viral specificity has been well documented.(10)

 

Third, reverse transcription. If reverse transcriptase activity were a unique

feature of retroviruses, it could have been an interesting molecular marker.

Unfortunately, it has been shown that reverse transcriptase is found in the

uninfected cells of yeasts, insects and mammals (11) and " has nothing to do with

retroviruses as such " as well referenced in a recent report from S. Lanka.

Moreover, K. Mullis himself does not support the use - to amplify and quantify

the " HIV genome " - which is being made of the PCR methodology he developed,

which is the current method of " measuring the viral load " in AIDS patients.

 

More disturbing is the fact that some 'markers' are searched for in the 1.16

gradient sedimenting material which is the density where intact virions are

expected to be found, but not their molecular fragments. If lysed retrovirus

particles released molecular markers, the 1.16 samples should at least initially

allow investigators to demonstrate virus particles by EM. They don't. however

after 15 years of most intensive HIV research, two independent groups finally

decided to explore by electron microscopy the ultrastructural features of the

material sedimenting at the 1.16 density. Working on " HIV-1 infected T-cell "

cultures supernatants, both groups found that it contains primarily cellular

debris and cell membrane vesicles which could definitely not be identified with

HIV particles and rare " virus-like " particles.(12, 13) Still, this is the type

of sample in which " viral markers " are currently identified and used to measure

the effects of anti-viral drugs in current clinical trials.

 

In conclusion, and after extensive reviewing of the current AIDS research

literature, the following statement appears inescapable: neither electron

microscopy nor molecular markers have so far permitted a scientifically sound

demonstration of retrovirus isolation directly from AIDS patients. This

conclusion fully confiens the recent reports published in Continuum by E.

Papadopulos and by S. Lanka.

 

Harvey Bialy, editor of the journal Bio/Technology has stated that (14) " A

powerful hypothesis has to explain and predict. What kind of scientist continues

to support a hypothesis that fails to explain and fails to predict? " The

HIV/AIDS hypothesis fails to explain the considerable drop of T4 circulating

lymphocytes in AIDS patients. It predicted a dramatic AIDS epidemic which was

never observed (unless we accent the CDC's most surprising redefinition of AIDS

as including some 31 " AIDS defining illnesses " !).

 

Obviously, the HIV/AIDS hypothesis has to be scientifically reappraised.(15)

And, most urgently, the funding for AIDS research should no longer be restricted

to laboratories working on an hypothesis which has never been proven. *

 

References

 

1. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM, Causer D,

Hedland-Thomas 13, Page B, 1994. A critical analysis of the HIV-T4-AIDS

hypothesis. Genetica 95:5-24

 

2. Lanka, Stefan, 1994. Fehldiagnose AIDS? Wechselwirkung, Aachen, December,

48-53.

 

3 de Harven, E, 1974. remarks on the ultrastructure of type A, B and C virus

particles. Advances in Virus Research 19: 221-264. Academic Press, Inc., publ.,

New York.

 

4. Lwoff A, Horne R, Tournier P, 1962. Cold Spring Harbour Symposium on

Quantitative Biology 27:51.

 

5 de Harven E, and Friend C, 1960. Further electron microscope studies of a

mouse leukemia induced by cell-free filtrates. J. Biophysic. and Biochem.

Cytol., vol 7, 747-752. Rockefeller University Press, New York

 

6. de Harven E, 1965. Remarks on viruses, leukemia and electron microscopy. In

Methodological approaches to the study of leukemias. V Defendi, edit., The

Wistar Institute Press publ, Philadelphia, pp147-156

 

7. de Harven E, 1965. Viremia in Friend leukemia: the electron microscope

approach to the problem Pathologie-Biologie,13:125-134 de Harven E, 1998.

Pioneer deplores " HIV " . Continuum vol 5, page 24

 

8. Sinoussi F, Mendiola L, Chermann JC, 1973. Purification and partial

differentiation of the particles of murine sarcoma virus (M.MSV) according to

their sedimentation rates in sucrose density gradients. Spectra 4:237-24

 

9. Papadopulos-Eleopulos E, Turner VF and Papadimitnou JM, 1993. Is a positive

Western Blot proof of HIV infection? Bio/Technology 11:696-707

 

10. Todak C, Klein E, Lange M et al., 1991. A clinical appraisal of the p24

antigen test. International Conference on AIDS, vol 1, Florence, Italy

 

11. Varmus H, 1987. Reverse transcription Sci. Am. 257:48-54

 

12. Gluschankof P. Mondor I, Gelderblom HR, and Sattentau QJ, 1997. Cell

Membrane vesicles are a major contaminant of gradient-ennched human

immunodeficiency virus type-l preparations. Virology 230:125-133

 

13. Bess JW Jr., Gorelick WJ, Bosche WJ, Henderson LE, and Arthur LO, 1997.

Microvesicles are a source of contaminating cellular proteins found in purified

HIV-I preparations. Virology 230:134-144

 

14. Farber, C, 1992. Fatal distraction, Spin Magazine, June 1992

 

15. Philpott P, 1997. The isolation question. Reappraising AIDS, vol 5 number 6,

1-12

 

 

Author's address:

Dr Etienne de Harven

le Mas Pitou,

2879 Route de Grasse

06530 Saint Cezaire sur Siagne, France

 

 

VIRUSMYTH HOMEPAGE

 

 

-Allen Graves IBWB ( U.S.A. )

" Do not let either the medical authorities nor the politicians mislead you. Find

out what the facts are, and make your own decisions about how to live a happy

life and how to work for a better world. " - Linus Pauling

 

Sites that I've found to be helpful/informative ;

 

aidscured A good forum for those who are

seeking a non-pharmaceutical solution to illness(es).

AIDSsoc This forum focuses on the

societal aspects of the " AIDS " myth.

http://www.aliveandwell.com A more rational, informed perspective on

" AIDS " .

http://www.virusmyth.com Exposing the erroneous science behind current

" HIV/AIDS " thinking.

http://www.aidsmythexposed.com Forum with a " WAR On AIDS Science "

conscious focus.

 

Sites of " ultimate concern " ;

 

http://www.lucistrust.org/links/index.shtml

http://www.lucistrust.org/goodwill/links.shtml

 

 

 

 

 

 

Link to comment
Share on other sites

Hi there! AIDS is an Industry, and many patients are religiously

compliant in taking their meds. in often complicated regimes. The money

involved in the current AIDS strategy is shocking. Interesting how no

mention of side effects emerges, and more interesting how accepting many

patients are of the disastrous effects. Hydroxurea is known to cause

death by heart attacks. One of the protease inhibitors causes the death

of the blood supply to the large joints. I know one patient, who has had

one hip replacement, is due to have the other hip replaced, as well as

needing both knees and a shoulder replaced, because the bone died in

those areas. Very strangely, some drugs are causing rectal tears that

result in infections, and are usually dealt with surgically -- but can

recur. Cosmetic effects are facial wasting, a skeletal effect, and large

deposits of fat around internal organs, resulting in " the paunch " .

Explosive diarhea is common. The expenses of the most recent conference

on AIDS would have likely provided some basic necessities like food and

simple health care in the Third World, for persons with AIDS. The whole

system is unbeleivably corrupt, self-sustaining, with as much intention

of curing AIDS , as the Cancer Industry has of curing cancer and ending

the careers and empires built on the suffering of others. Left to the

'Experts', all will continue as it has, with newer drugs and more

research money to keep the whole system viable. Steve

 

Frank wrote:

 

>http://www.nytimes.com/2003/09/23/health/23IMMU.html?th

>

>September 23, 2003Trying to Kill AIDS Virus by Luring It Out of HidingBy DONALD

G. McNEIL Jr.

>

>

>ho knows what evil lurks in the lymph nodes of men?

>

>The immunologist knows.

>

>But the body may not even suspect it.

>

>That evil is the AIDS virus, which has the power to hibernate, virtually

forever, even in patients taking their triple-therapy cocktails with religious

devotion.

>

>Many AIDS specialists are working on ways to tease the virus out of hiding so

it can be killed, and real progress has been made. A laboratory at the

University of California at Los Angeles recently reported 80 percent success in

mice.

>

>Even that, however, cannot stop the virus from roaring back. " Eighty percent is

close, " said Dr. Roger J. Pomerantz, an AIDS researcher at Thomas Jefferson

University in Philadelphia. " But close only counts in horseshoes and hand

grenades. "

>

>Even if the virus, battered by the combination punching of antiretroviral

therapy, is found in just one dormant T cell in a million, repeated tests in

humans have shown that it will re-emerge if the therapy stops.

>

>Simply hunting it is a ticklish business, because the virus hides in the same

memory T cells that act as triggers for the immune system. Failing to " light up "

the virus in them will keep it hidden. But activating too many T cells means a

cascade of immune reactions like those in toxic shock syndrome, possibly killing

the patient.

>

>Since beginning their quest 19 years ago with the realization that infected T

cells somehow slept in " reservoirs " in the lymph glands, blood and perhaps in

parts yet unknown, researchers have experimented with immune-boosting drugs

borrowed from cancer therapy and with tiny " smart bombs " that use antibodies to

hunt for one cell among billions and kill it with a minuscule dose of poison.

>

>Despite regular advances, some prominent AIDS researchers worry that the task

may be hopeless.

>

> " It's a very, very, very difficult situation, " Dr. Anthony S. Fauci, director

of the National Institute of Allergy and Infectious Diseases, said. " You can get

a reservoir down to an undetectable level, and then if someone gets even a

little blip of viremia, it can reseed the area, and you're back to Square 1. "

>

>That " blip of viremia, " a jump in virus circulating in the bloodstream, can be

set off even by a bout of flu or a rusty nail, because the AIDS virus can hide

in a T cell that normally attacks the flu virus or tetanus.

>

>Dr. Robert C. Gallo, director of the Institute of Human Virology at the

University of Maryland, said many labs had attacked latent virus, with no

breakthrough success yet.

>

>The newest work, at U.C.L.A.'s AIDS Institute, was in mice bred without immune

systems in which human thymus cells were implanted and infected. Although he

praised the research, Dr. Gallo said the mouse-thymus model was " a very

artificial system. "

>

> " If you had this in a monkey model, with demonstrable safety data, " he said,

" that would merit highlighting it. "

>

>The U.C.L.A. team, led by Dr. Jerome A. Zack and Dr. David G. Brooks, used

interleukin-7 and prostratin to light up infected cells. If humans were given

big enough doses to reach the most hidden cells, " I don't know that it wouldn't

be terribly dangerous, " Dr. Gallo said.

>

>The AIDS virus is frequently described as wily for its ability to mutate

drug-resistant forms. But it is equally wily in its hibernation style, sitting

as silent as a nuclear submarine on the ocean floor. Incorporated into the DNA

of a shrunken, inactive T cell, the virus is a mere speck of genetic code,

10,000 base pairs out of the 6 billion in each human nucleus.

>

> " It exists as pure information, " Dr. Robert F. Siliciano, an AIDS researcher at

the Johns Hopkins University, said. " The immune system can't see it, because the

system sees proteins, and it's not making proteins. The drugs don't touch it,

because they stop replication, and it's not replicating. "

>

>Dr. Siliciano recently demonstrated that the numbers of infected dormant cells

remained steady over 7 years and might take 70 years to die off under normal

antiretroviral assault. Trying to defeat that, researchers try ever more

complicated regimens.

>

>Dr. Fauci described treating 10 patients with multiple cycles of interleukin-2

to " flush the virus out. "

>

> " We thought the cells would spit out their virus and die, which would take care

of those suckers, and then antiretrovirals would stop proliferation, " he said.

>

>After a moment of jubilation when he found no virus even in biopsies from his

patients' lymph nodes, he went for " the proof of the pudding " and took the

patients off their AIDS drugs.

>

> " Everyone rebounded, " he said. " We failed. "

>

>Mike Flanagan, 41, an architect, was in an even harsher pharmacological study

led by Dr. Pomerantz. He was chosen, he said, because he knew the exact date

when he was infected and was very good at taking his pills on time.

>

>He was hospitalized to begin receiving a mix of eight AIDS and cancer drugs,

including antiretrovirals, interleukin-2, hydroxyurea and OKT-3.

>

> " It was pretty rough, " Mr. Flanagan said. " I got really paranoid, and I had

trouble sleeping. "

>

>After another year as an outpatient, he was told to stop all drugs and wait.

>

>In three months, " it came back, " he said, conceding disappointment. " A lot of

people put a lot of energy into that test, and I felt like I let them down. I

thought there was a chance it would work. "

>

>In the U.C.L.A. study, released last week by the journal Immunity, Dr. Zack

described choosing his drugs — prostratin and interleukin-7, to " tickle the

cell, just turn the virus on without turning on the cell. "

>

>A " turned-on " virus, Dr. Zack explained, displays some of its proteins on the

surface of the T cell, but does not prod the cell to divide or to wake up other

T cells to begin an immune system assault on a foreign invader.

>

> " Then we come in with the immunotoxin, " he said. It is a molecule-size smidgen

of bacterial poison attached to an antibody that gloms onto the T cell and

injects the toxin.

>

>Immunotoxins are too poisonous to use alone against AIDS, but they may work in

combination with antiretrovirals, he said. If all goes well, he will try the

tactic in monkeys and then humans.

>

>But, Dr. Zack conceded, killing even 80 percent of the latent virus is probably

not enough to finish the job. He may try more " tickling " drugs in combination or

he may give the drugs in pulses. " Maybe, " he said, " we can do better. "

>

>Copyright 2003 The New York Times Company

>

>

>NEW WEB MESSAGE BOARDS - JOIN HERE.

>Alternative Medicine Message Boards.Info

>http://alternative-medicine-message-boards.info

>

>

>

>

>

>

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...